Use of a VEGF antagonist to treat angiogenic eye disorders
US-11707506-B2 · Jul 25, 2023 · US
Regeneren Pharmaceuticals Inc holds 9 patents in our database, with recent filings and technology areas summarized below.
| Metric | Value |
|---|---|
| Total patents | 9 |
| Recent patents | 2 |
| First publication | Feb 2, 2021 |
| Latest publication | Jul 25, 2023 |
Year-over-year patent counts for this assignee.
Latest publications where this party is an assignee.
US-11707506-B2 · Jul 25, 2023 · US
US-11701427-B2 · Jul 18, 2023 · US
US-11576356-B2 · Feb 14, 2023 · US
US-11479602-B2 · Oct 25, 2022 · US
US-11104730-B2 · Aug 31, 2021 · US
Representative or frequently cited publications from precomputed assignee stats.
US-11707506-B2 · Jul 25, 2023 · US
US-11701427-B2 · Jul 18, 2023 · US
US-11576356-B2 · Feb 14, 2023 · US
US-11479602-B2 · Oct 25, 2022 · US
US-11104730-B2 · Aug 31, 2021 · US
Mapped technology topics for this assignee.
| Technology | Patents |
|---|---|
| Human Necessities | 9 |
| Chemistry & Metallurgy | 8 |
| Operations & Transport | 1 |
| Cross-Sectional Technologies | 1 |
Answers are generated from the same data shown on this page.